Krystal Biotech Reaches New 52-Week High of $326.07

Krystal Biotech, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 326.07 on June 11, 2026. This achievement underscores the company's robust performance over the past year, with a remarkable increase of 81.84%, significantly outpacing the S&P 500's growth of 22.78% during the same period. The company's market capitalization stands at USD 7,173 million, reflecting its position within the small-cap segment. Krystal Biotech's price-to-earnings (P/E) ratio is currently at 35.00, indicating investor sentiment towards its earnings potential. Additionally, the company maintains a return on equity of 16.80%, showcasing its efficiency in generating profits from shareholders' equity. With a price-to-book ratio of 5.88 and a debt-to-equity ratio of -0.68, Krystal Biotech appears to be managing its financial structure effectively. The stock's previous 52-week low was recorded at USD 127.99, highlighting the significant upward movement in its valuation. This milestone reflects the company's ongoing developments and market positioning within the competitive biotechnology landscape.